Cargando…
Development of [(18)F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
Expression of programmed cell death ligand 1 (PD-L1) within tumors is an important biomarker for guiding immune checkpoint therapies; however, immunohistochemistry-based methods of detection fail to provide a comprehensive picture of PD-L1 levels in an entire patient. To facilitate quantification of...
Autores principales: | Lesniak, Wojciech G., Mease, Ronnie C., Chatterjee, Samit, Kumar, Dhiraj, Lisok, Ala, Wharram, Bryan, Kalagadda, Venkateswara Rao, Emens, Leisha A., Pomper, Martin G., Nimmagadda, Sridhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563393/ https://www.ncbi.nlm.nih.gov/pubmed/31187691 http://dx.doi.org/10.1177/1536012119852189 |
Ejemplares similares
-
Peptide-Based (68)Ga-PET Radiotracer for
Imaging PD-L1 Expression in Cancer
por: De Silva, Ravindra A., et al.
Publicado: (2018) -
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
por: Chatterjee, Samit, et al.
Publicado: (2016) -
A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts
por: Azad, Babak Behnam, et al.
Publicado: (2016) -
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017) -
An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications
por: Lesniak, Wojciech G., et al.
Publicado: (2022)